Rodothea Amerikanou,Jonathan Lambert,Samah Alimam
Rodothea Amerikanou
Myeloproliferative neoplasms (MPNs) are clonal stem cell disorders commonly diagnosed in the seventh decade of life. With increasing access to blood surveillance, the number of adolescent and young adults (AYAs) diagnosed with MPNs is incre...
Antoine N Saliba,Naseema Gangat
Antoine N Saliba
Myeloproliferative neoplasms (MPN) have an inherent risk of transformation into blast phase (MPN-BP) or accelerated phase (MPN-AP) which is characterized by presence of ≥20% or 10-19% peripheral blood or bone marrow blasts, respectively. P...
Donal McLornan
Donal McLornan
Update on diagnostic approaches and therapeutic strategies in systemic mastocytosis [0.03%]
系统性肥大细胞增生症的诊断方法和治疗策略进展
Deepti H Radia,Mufaddal T Moonim
Deepti H Radia
Systemic mastocytosis is a rare disease which is being better recognized and managed. While the vast majority of patients have indolent disease with variable symptom burden, a small proportion evolve or present with aggressive disease. This...
Challenges of diagnosing and managing pre-fibrotic myelofibrosis: A case-based and practical approach [0.03%]
前纤维性髓纤的诊断和管理挑战：基于病例且实用的方法论
Alexandros Rampotas,Rupen Hargreaves,Donal P McLornan
Alexandros Rampotas
Pre-Fibrotic Myelofibrosis is a frequently under-recognised entity that has distinct features separate to those of both Essential Thrombocythaemia and overt Primary Myelofibrosis. Misdiagnosis is relatively common due to subtle differences ...
Douglas Tremblay,Ruben Mesa
Douglas Tremblay
Patients with myeloproliferative neoplasms (MPNs) suffer from often debilitating constitutional symptoms that negatively impact quality of life to a degree similar to patients with metastatic solid tumors. Despite heterogeneity in the bread...
Considerations to comprehensive care for the older individual with myelofibrosis [0.03%]
骨纤维化老年患者综合治疗需考虑的因素
Donal P McLornan,Christopher J Saunders,Claire N Harrison
Donal P McLornan
Over the last decade, we have witnessed a massive increase in available clinical agents, both in the clinical trial setting and following commercial use approval, directed to reduced life expectancy as well as the considerable symptom, sple...
Julian A Waksal,Douglas A Tremblay
Julian A Waksal
Polycythemia vera (PV) is characterized by clonal proliferation of a hematopoietic stem cell leading to erythrocytosis. Patients with PV have significantly higher morbidity and mortality compared to the general population due to increased r...
Juan-Carlos Hernández-Boluda,Tomasz Czerw
Juan-Carlos Hernández-Boluda
Myelofibrosis (MF) is a chronic myeloproliferative neoplasm with a very heterogenous clinical course. Median survival of patients with overt MF is close to 6 years, but with great individual variability. Allogeneic hematopoietic cell transp...
Javier Soto Alsar,Ana Gutiérrez Ortiz de la Tabla,Laura Ortega Morán et al.
Javier Soto Alsar et al.
Anticoagulation is the cornerstone of cancer-associated VTE treatment, including vitamin K antagonists (VKA), unfractionated heparin (UFH), fondaparinux, low-molecular-weight heparins (LMWH) and direct oral anticoagulants (DOACs). The goals...